ABSTRACT
Dopaminergic drugs have been used for the treatment of restless legs syndrome (RLS) since the first description of their efficacy in 1982 (1). Since then, the overall long-term efficacy of these drugs has been well established by several retrospective studies (2-5). Side effects are generally mild (4), and contrary to their use in Parkinson’s disease (PD), no cases of dyskinesias have been reported to date (4,6-8).
